MedPath

Effect of supplementation in treatment of women with polycystic ovary syndrome

Phase 3
Conditions
Polycystic ovary syndrome.
Polycystic ovarian syndrome
E28.2
Registration Number
IRCT201605225623N81
Lead Sponsor
Vice chancellor for research, Arak University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
60
Inclusion Criteria

Patients with PCOS according to Rotterdam criteria
Aged 18 to 40 years

Exclusion Criteria

Pregnant women
Individuals with metabolic diseases
Thyroid disease
Hyperprolactinemia
Hypercortisolemia
Renal and liver diseases

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Beck score. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;GHQ score. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;DASS-28 score. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.
Secondary Outcome Measures
NameTimeMethod
Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.
© Copyright 2025. All Rights Reserved by MedPath